A groundbreaking medical breakthrough is taking place in Latin America, and it's time to shine a spotlight on this incredible advancement. Brazil's Ribeirão Preto is leading the way with a homegrown CAR-T cancer therapy, offering hope to patients across the region.
But here's where it gets controversial: this therapy, which has the potential to revolutionize cancer treatment, is now accessible at a fraction of the usual cost, thanks to significant public investment. And this is the part most people miss: it's not just about the price tag; it's about expanding access to cutting-edge care and bringing hope to those who need it most.
Let's dive into the details of this remarkable development.
The Nutera Center's Impact:
The Nutera Center, backed by over R$ 200 million in public funding, is now delivering Latin America's first fully homegrown CAR-T therapy. This investment has enabled a remarkable reduction in treatment costs, with per-patient expenses estimated at around R$ 350,000 (US$ 66,000), significantly lower than imported alternatives.
The Carthedrall Clinical Study:
Currently underway is the Carthedrall Clinical Study, an ambitious program aiming to treat 81 patients across five hospitals. Phase 2 of the study was authorized in January 2025, and while detailed results are yet to be disclosed, early cases have shown dramatic clinical improvements.
Nutera's CAR-T Protocol:
Nutera's CD19-targeted CAR-T protocol employs a vein-to-vein process lasting between 45 and 60 days, followed by inpatient monitoring for potential inflammatory toxicities. This innovative approach has shown promising results in treating refractory B-cell malignancies, with international data indicating robust remission rates: 28-68% for lymphomas (2 years) and 62-86% for leukemias (1 year).
Future Expansions:
Looking ahead, Nutera plans to expand its trials to include autoimmune and neurologic B-cell-mediated diseases. A highly anticipated lupus study is expected to commence in 2026, further broadening the reach of this groundbreaking therapy.
A Historic First for Latin America:
For the very first time in Latin America, patients suffering from blood cancers are benefiting from a CAR-T cell therapy developed entirely within the region. This therapy is being administered in Ribeirão Preto, a major city in Brazil's São Paulo state, as part of a scientific study targeting B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
The Birth of Nutera-RP:
The Advanced Therapy Center of Ribeirão Preto, or Nutera-RP, was established in 2022 through a partnership between the Ribeirão Preto Blood Center, the University of São Paulo, and the Butantan Institute. Both the state and federal governments invested over R$ 200 million in Nutera's infrastructure, supplies, and technical staff, a strategic move to foster the development and independence of Brazil's health sector.
Reducing Treatment Costs:
One of the key objectives of this initiative is to make CAR-T therapy more affordable. Traditionally, treating a patient with CAR-T can cost upwards of US$ 500,000, excluding hospital expenses. This high cost has limited its availability in Brazil's public system, with only around 120 people benefiting from this technology since 2019. In contrast, over 30,000 patients in the United States and 10,000 in Europe have undergone CAR-T cell treatment.
Nutera's Mission:
As Latin America's largest and most advanced cancer treatment program, Nutera is committed to changing this reality. Through their efforts, the cost per patient in the ongoing Carthedrall Clinical Study has been reduced to R$ 350,000 (US$ 66,000). Nutera aims to treat more than 300 patients annually with their innovative CAR-T technology in the near future.
Understanding CAR-T Therapy:
CAR-T cell therapy harnesses the power of a patient's own immune cells to combat blood cancers. The concept was first demonstrated by Israeli immunologist Zelig Eshhar in 1989. Since then, groups in the United States have worked tirelessly to perfect the manipulation of these cells and enhance the therapy's safety. In the early 2010s, they began applying it experimentally to terminally ill cancer patients, leading to positive results that prompted the FDA to unanimously approve CAR-T therapy for cancer treatment in 2017. The following year, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Medicine for their contributions.
How Nutera's Therapy Works:
The therapy employed at Nutera involves collecting a patient's blood and isolating their T-cells, a type of white blood cell that fights infections in various ways. These T-cells are then genetically engineered by adding a new gene using a modified, deactivated virus. This gene enables the creation of a chimeric antigen receptor (CAR) on the T-cell's surface, designed to recognize and bind to CD19, an antigen specific to B-cells (both healthy and tumoral). B-cells play a central role in this therapy as both B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma arise from the abnormal proliferation of B-cells.
Next, the engineered T-cells are cultivated in a nutrient-rich liquid for at least 10 days, allowing them to multiply into tens of millions. After this, the cells are frozen and undergo a rigorous quality control process to ensure they are free from viruses, bacteria, or fungi. The patient then undergoes a five-day light chemotherapy to eliminate their existing T-cells, a process known as lymphoid depletion, which is crucial for the success of CAR-T cell therapy. It creates an optimal environment by reducing tumor load, removing immunosuppressive cells, and making cytokines available for the CAR-T cells to expand and persist.
After a two-day rest, the CAR-T cells are infused into the patient. Once these cells bind to the cancer cells, they trigger the tumorous cells to die, offering a sustained immune response against the cancer and potentially leading to long-term remission.
The Carthedrall Clinical Study:
Nutera's Carthedrall Clinical Study has received substantial funding, with R$ 100 million (US$ 18 million) from Brazil's Ministry of Health. Initiated in 2024, Carthedrall aims to treat 81 patients in five reference hospitals who have B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma and have either experienced a disease recurrence or did not respond to standard treatments like chemotherapy and bone marrow transplants.
A Journey of Progress:
Prior to Nutera's Carthedrall Clinical Study, CAR-T therapy had been offered on an experimental basis to only 20 individuals in Brazil, starting in 2019. The excellent results of this initial trial were published in 2024 in the magazine Bone Marrow Transplantation, providing crucial support for the authorization of the Carthedrall trial.
Carthedrall Clinical Study is divided into two phases, with the second phase authorized in January 2025. This authorization allows Nutera's partner hospitals to recruit and treat patients, who will be monitored by the medical team for five years. Dr. Diego Villa Clé, hematologist and coordinator of both Nutera and the Carthedrall Clinical Study, estimates that by December of this year, a quarter of the 81 patients will have been treated, and the second phase of the study should conclude by the second semester of 2026.
While legal restrictions prevent Nutera from disclosing the ongoing study's results, Dr. Villa Clé confirms that there have been cases of dramatic improvement in patients' conditions.
A Therapy with Superior Results:
CAR-T cell therapy offers several advantages, including a reduction in chemotherapy sessions and pain medication, and an increased chance of complete or partial remission. A review article published in 2023 in the journal Nature Reviews Clinical Oncology by researchers from the American National Cancer Institute (NCI) highlighted these benefits. In the case of lymphomas, the rate of participants in whom the disease became undetectable two years after CAR-T treatment ranged from 28% to 68%. For leukemia, between 62% and 86% showed no signs of the disease one year after infusion. It's worth noting that these patients had not responded well to previous treatments and were often in critical condition.
Nutera's Future Goals:
While Nutera's current focus is on blood cancers, the center aims to expand the use of cell therapy to autoimmune diseases involving malfunctioning B-cells, such as lupus, rheumatoid arthritis, and systemic sclerosis. Additionally, there is potential for Nutera's CD19-targeting CAR-T cells to treat neurological diseases affecting B-cells, including myasthenia gravis and neuromyelitis optica.
"Nutera already has a study targeting lupus, awaiting authorization from the surveillance agency and the Research Ethics Committee. The resources are secured, and this study is expected to begin in 2026," says Dr. Villa Clé.
This groundbreaking work at the Nutera Center offers a glimmer of hope to patients across Latin America, demonstrating the power of innovation and public investment in healthcare. As we await further developments and results from the Carthedrall Clinical Study, it's clear that this therapy has the potential to transform the landscape of cancer treatment in the region.
What are your thoughts on this groundbreaking therapy? Do you think it has the potential to revolutionize cancer treatment in Latin America? Share your insights and opinions in the comments below!
